Client Profiles Among Medication Treatment Episodes for Opioid Use Disorder With and Without Co-occurring Mental Health Disorders
Abstract
Objectives To compare national medication treatment episodes for opioid use disorder with and without recorded co-occurring mental health disorders. Methods We analyzed 2023 US Treatment Episode Data Set-Discharges records for 109,115 publicly funded treatment episodes with methadone use at admission, known mental health comorbidity status, recorded sex, and discharge for completion, dropout, or facility termination. We compared demographics, substance use, treatment, and discharge characteristics. Results Episodes with co-occurring disorders (n = 56,403) more often involved female clients (40.2% vs 31.5%), White clients (67.4% vs 59.3%), injection drug use (37.1% vs 29.3%), alcohol use (26.0% vs 13.5%), cocaine or crack use (38.8% vs 20.3%), residential care (30.1% vs 11.4%), and prior treatment (85.4% vs 68.4%). Mean length of stay was shorter (128.0 vs 169.3 days). Conclusions Co-occurring mental health disorder status marked distinct client and service profiles. Public Health Implications: Opioid treatment programs should pair medication treatment with systematic mental health, polysubstance-use, and discharge-support planning.
Related
- Bipolar Treatment History Form (BTHF): a new instrument to rate the adequacy of medication trials for the treatment and prevention of manic or hypomanic episodes
- Medication history, not clinical profiles, predicts antihypertensive treatment persistence across health systems
- Attention-Deficit/Hyperactivity Disorder (ADHD) Temperament Profiles Predict Treatment Response to Combined Medication and Behavioral Intervention
- Antiseizure medication-induced changes in serum ephrin-B2 and their association with treatment response in adults with generalised seizure disorders in Northern India: protocol for a prospective observational cohort study
- Medication use and treatment patterns in children and adolescents with chronic tic disorders: an EMTICS study
BibTeX
@misc{howard2026client,
title = {{Client Profiles Among Medication Treatment Episodes for Opioid Use Disorder With and Without Co-occurring Mental Health Disorders}},
author = {Daniel L. Howard and Kechen Zhao and Alanis Goncalves Leite and Yinfei Kong},
howpublished = {Research Square},
year = {2026},
month = oct,
doi = {10.21203/rs.3.rs-10656455/v1},
url = {https://doi.org/10.21203/rs.3.rs-10656455/v1},
note = {CC BY 4.0},
}
RIS
TY - UNPB
TI - Client Profiles Among Medication Treatment Episodes for Opioid Use Disorder With and Without Co-occurring Mental Health Disorders
AU - Daniel L. Howard
AU - Kechen Zhao
AU - Alanis Goncalves Leite
AU - Yinfei Kong
PY - 2026
DA - 2026/10/16
PB - Research Square
DO - 10.21203/rs.3.rs-10656455/v1
UR - https://doi.org/10.21203/rs.3.rs-10656455/v1
AB - Objectives To compare national medication treatment episodes for opioid use disorder with and without recorded co-occurring mental health disorders. Methods We analyzed 2023 US Treatment Episode Data Set-Discharges records for 109,115 publicly funded treatment episodes with methadone use at admission, known mental health comorbidity status, recorded sex, and discharge for completion, dropout, or facility termination. We compared demographics, substance use, treatment, and discharge characteristics. Results Episodes with co-occurring disorders (n = 56,403) more often involved female clients (40.2% vs 31.5%), White clients (67.4% vs 59.3%), injection drug use (37.1% vs 29.3%), alcohol use (26.0% vs 13.5%), cocaine or crack use (38.8% vs 20.3%), residential care (30.1% vs 11.4%), and prior treatment (85.4% vs 68.4%). Mean length of stay was shorter (128.0 vs 169.3 days). Conclusions Co-occurring mental health disorder status marked distinct client and service profiles. Public Health Implications: Opioid treatment programs should pair medication treatment with systematic mental health, polysubstance-use, and discharge-support planning.
SN - 2693-5015
ER -